BRIEF-Mesoblast provides update on global heart failure program

* Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.